Loading organizations...
Nanovery engineers a platform utilizing Nucleic Acid Nanorobotics (NANs) for molecular testing. Employing DNA nanotechnology, company develops precise nanorobotic sensors for robust nucleic acid sequence detection and quantification. This technology simplifies complex analysis, offering solutions for RNA therapeutic bioanalysis, custom assay development, and microRNA biomarker identification.
Founded in 2018 by CEO Jurek Kozyra and COO Roma Galloway, Nanovery aimed to innovate molecular diagnostics. Kozyra, an expert in DNA nanodevices, joined Galloway, experienced in biological and medicinal chemistry. Their core insight was harnessing engineered DNA structures for rapid, reliable, simplified detection in applications like early disease diagnosis.
Nanovery’s solutions target researchers and industrial partners needing efficient nucleic acid analysis. Integrating DNA nanotechnology with AI, the company provides powerful insights from biological samples for RNA therapeutics and biomarker discovery. Nanovery aims to accelerate scientific progress, transforming diagnostics and enabling earlier disease detection.
Nanovery has raised $1.0M across 1 funding round.
Nanovery has raised $1.0M in total across 1 funding round.
Nanovery has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Series U in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $1M Series U | — | Northstar Ventures | Announced |
Nanovery is a biotechnology company founded in 2018 that develops nucleic acid nanorobotics (NANs), a patented platform using DNA nanotechnology for precise RNA therapeutic analysis, biomarker quantification, and early disease detection like cancer.[1][2][3] Its products, such as trASO® and trasiR®, enable enzyme-free, scalable testing of nucleic acids in liquid samples via fluorescent signals read by standard plate readers, serving pharmaceutical companies, biotech firms, and researchers developing RNA therapies like ASOs and siRNAs.[2][3] The company solves key challenges in biotech by simplifying workflows, reducing costs, time, and variability compared to traditional methods requiring extraction, while supporting chemically modified sequences for drug development and diagnostics.[1][3][4] Nanovery has raised $4.39M total, including a recent £1.1M (~$1.47M) round one month ago, achieved seed VC-III stage, secured Innovate UK grants, and piloted with two top-10 pharma companies, employing nine staff plus PhD students.[1][3][4]
Nanovery was co-founded in 2018 in Newcastle upon Tyne, UK, by Jurek Kozyra (CEO, deep tech entrepreneur and researcher) and Roma Galloway (COO, with biological and medicinal chemistry expertise), who aimed to create efficient diagnostics for serious diseases like cancer using nanorobots for earlier detection via liquid biopsies.[1][3][4][5] The idea emerged from advancing liquid biopsy tech to make it faster, cheaper, and less laborious, targeting clinically relevant mutations in cancer cells.[4] Early traction came from a Newcastle University Arrow project proving prototype feasibility in lab-grown cancer cells, which unlocked Innovate UK grants, £1.85M investment, operations at Newcastle Helix Biosphere, and team expansion to nine plus two PhD students.[4] Pivotal moments include patenting NANs tech (one patent in analytical chemistry, biotech, DNA), SLAS Europe Innovation Avenue award, and recent pilots with global pharma leaders.[1][3]
Nanovery rides the RNA therapeutics boom, fueled by mRNA vaccine success post-COVID, driving 11-fold M&A surge in 2020-2021 and demand for sensitive tools in ASO/siRNA drug development and diagnostics.[3] Timing aligns with expanding RNA markets needing scalable, reliable bioanalysis amid rising liquid biopsy adoption for early cancer detection (affecting 1-in-2 people), where Nanovery slashes costs/turnaround to broaden access.[1][4] Favorable forces include biotech's shift to nanotechnology/AI for precision, plus UK ecosystem support via Innovate UK and Newcastle University.[4] It influences by accelerating therapies to patients, partnering with pharmas/biotechs, and pioneering NANs to shape nucleic acid testing standards.[2][3]
Nanovery's momentum—fresh funding, pharma pilots, product launches—positions it to capture RNA analytics growth, expanding from bioanalysis to full diagnostics pipeline amid surging demand for fast, affordable testing.[1][3] Upcoming trends like AI-enhanced nanotech and mRNA expansions will amplify its edge, potentially scaling via more pharma deals and global adoption. Its influence may evolve from UK innovator to ecosystem shaper, fast-tracking life-changing therapies as biotech prioritizes precision at speed—echoing its founding vision of accessible early detection.[2][4]
Nanovery has raised $1.0M in total across 1 funding round.
Nanovery's investors include Northstar Ventures.
